Dr Reddy launches Desmopressin Acetate injection USP

Dr Reddy's Laboratories informed the bourses today that its subsidiaries have launched Desmopressin Acetate injection USP, 4 mcg/ml single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) injection, 4 mcg/ml, approved by US Food & Drug Administration (USFDA).

DDAVP (desmopressin acetate) injection USP brand and generic market had US sales of approximately $20.9 million MAT for the most-recent twelve months, ending in March 2020. Dr Reddy’s Desmopressin Acetate injection USP, 4 mcg/ml is available in a carton of ten 1 ml single-dose ampules.

The stock of Dr Reddy, which opened today on a positive bias, surged nearly 1.5 per cent to touch an intraday high of Rs 3,879.

Dr Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad (Telangana) in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.